Título : Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability |
Autor : Espadas, Cristina Ballester, Purificación Londoño, Ana Carolina Almenara, Susana Aguilar, Víctor Belda, César Pérez, Enrique Peiró, Ana |
Editor : Elsevier |
Departamento: Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica |
Fecha de publicación: 2020-07 |
URI : https://hdl.handle.net/11000/32327 |
Resumen :
Nowadays, adults with autism spectrum disorder (ASD) experience several comorbidities whose treatment implies a wide range of psychotropic prescriptions. This study aimed to evaluate medication-related safety, drugdrug interactions, and psychotropics prescription trends. We conducted an observational and multicentric
pharmacovigilance study in subjects with ASD and Intellectual disability (ID, n = 83). Clinical information
(diagnoses, ongoing medications, comorbidities [multimorbidity ≥ 4 chronic health conditions]) and psychotropic prescriptions (polypharmacy ≥ 4 chronic drugs, daily drug doses, co-prescription) were registered.
Ethical approval for this study was obtained. Participants (30±10 years old, 86% men, BMI 27±6 kg/m2)
displayed 37% multimorbidity (mean of 3, IQR 2–4), and 57% polypharmacy (13% out of dose recommended
range). Most drugs prescribed were psychotropic risperidone which is related to nervous system comorbidities
(18% epilepsy, 16% insomnia, and 14% psychotic agitations). Risperidone and quetiapine were co-prescribed in
60% of the cases without any monitoring adverse event routine. The rates of multimorbidity and polypharmacy,
among our young adults with ASD and ID, are concerning. Data suggest the need to develop a pharmacovigilance monitoring system to evaluate prescription accuracy, long-term safety of ongoing medications, and the fixed doses in this autistic population with associated ID.
|
Palabras clave/Materias: Autism spectrum disorder Intellectual disability Polypharmacy Adverse events Pharmacovigilance Multimorbidity |
Tipo de documento : info:eu-repo/semantics/article |
Derechos de acceso: info:eu-repo/semantics/closedAccess |
DOI : https://doi.org/10.1016/j.psychres.2020.113321 |
Aparece en las colecciones: Artículos Farmacología, Pediatría y Química Orgánica
|